Federal Register Notice: FDA has determined the regulatory review period for Vernalis, Ltd.’s Frova is 2,201 days for the extension of two patents that claims that human drug product. Frova (frovatriptan succinate) is indicated for the acute treatment of migraine attacks with or without aura in adults. To view this notice, click here.
